Home » Posts tagged with » Roche
Dicerna, Roche strike $1.67bn deal for hepatitis B virus therapies

Dicerna, Roche strike $1.67bn deal for hepatitis B virus therapies

Dicerna Pharmaceuticals has secured a research collaboration and licensing deal worth up to $1.67 billion with Roche to develop new drugs for chronic hepatitis B virus (HBV) infection using its GalXC RNAi platform technology. The collaboration between the Dicerna Pharmaceuticals and the Swiss drugmaker will focus on the global development and commercialization of the former’s […]

FeDeriCa clinical trial results : Phase 3 trial in HER2-positive breast cancer meets primary endpoint

FeDeriCa clinical trial results : Roche’s Genentech reported that the phase 3 FeDeriCa study evaluating the investigational fixed-dose combination (FDC) of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase in HER2-positive breast cancer met its primary endpoint. The Perjeta and Herceptin combination, which was subcutaneously injected in combination with intravenous (IV) chemotherapy, showed non-inferior levels of […]

Continue reading …
TRACON begins phase 1 TJD5 clinical trial in advanced solid tumors

TJD5 clinical trial : US biopharma company TRACON Pharmaceuticals has dosed the first patient in a US phase 1 clinical trial of I-Mab Biopharma’s CD73 antibody TJD5 (TJ004309) in patients with advanced solid tumors. TJD5 will be dosed in the early-stage trial as a single agent and also in combination with Roche’s PD-L1 antibody TECENTRIQ […]

Continue reading …
Convelo, Genentech to collaborate on remyelination drugs for MS

US biotech company Convelo Therapeutics has signed an exclusive worldwide collaboration with Roche subsidiary Genentech to fast track discovery and development of novel remyelination drugs for the treatment of multiple sclerosis (MS) and other neurological disorders. Convelo Therapeutics, which is headquartered in Cleveraland, Ohio, is engaged in discovering a new class of drugs that regenerate the […]

Continue reading …
Clover Health launches chronic diseases-focused Clover Therapeutics

California-based healthcare company Clover Health has launched a new research subsidiary, called Clover Therapeutics, which will focus on developing drugs for older adults for the treatment of chronic diseases. Clover Therapeutics has started its journey by signing a research collaboration and license agreement with Roche’s subsidiary Genentech to better understand the genomic factors that increase […]

Continue reading …
Genentech gets Kadcyla FDA approval for post-surgery treatment of HER2+ EBC

Kadcyla FDA approval : Roche subsidiary Genentech has secured approval from the US Food and Drug Administration (FDA) for its breast cancer drug Kadcyla (ado-trastuzumab emtansine) for post-surgery treatment of HER2-positive early breast cancer (EBC) in patients with residual invasive disease who were subjected to before surgery taxane and Herceptin (trastuzumab)-based treatment. The Kadcyla FDA […]

Continue reading …
Roche in $4.3bn deal to buy gene therapy company Spark Therapeutics

Roche acquisition of Spark Therapeutics : Swiss pharma giant Roche has signed an all-cash deal worth $4.3 billion to acquire US gene therapy company Spark Therapeutics, as per the latest pharma acquisition news. Roche acquisition of Spark Therapeutics According to the merger terms, Roche will offer to buy 100% of Spark Therapeutics for $ 114.50 […]

Continue reading …
Tecentriq wins FDA approval for extensive stage small cell lung cancer

Tecentriq FDA approval : Roche subsidiary Genetech has bagged a new approval from the US Food and Drug Administration (FDA) for Tecentriq (atezolizumab), this time in combination with chemotherapy as the first-line treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC). The chemotherapy to be used for the indication alongside Tecentriq is […]

Continue reading …
Nordic Nanovector initiates Betalutin rituximab combo trial in 2L FL

Nordic Nanovector has announced the dosing of the first patient in a phase 1b clinical trial called Archer-1 for evaluating the combination of its investigational lymphoma drug Betalutin (177Lu-satetraxetan-lilotomab) with Roche cancer drug rituximab (RTX) as a second-line treatment for follicular lymphoma (2L FL). Rituximab is a CD20-targeting monoclonal antibody that is given as a […]

Continue reading …
Roche breast cancer drug combo cuts death rate and recurrence

Roche breast cancer drug, Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy has been demonstrated in a phase 3 trial to have cut the risk of disease recurrence besides increasing the life span of patients with an aggressive form of early breast cancer. Roche Breast Cancer Trial APHINITY Results The breast cancer drug combination which met […]

Continue reading …